Accessing Innovation...
Serving Patients

NewBridge Pharmaceuticals specializes in in-licensing, acquiring, registering and commercializing FDA, EMA/European and Japanese PMDA approved therapeutics to address the unmet medical needs of diseases with high regional prevalence in the Middle East, Africa, Turkey and Caspian (AfMET) Regions.

What defines our path for today and the future is our four key strategic imperatives.

Understand our strategy

We bring innovative therapies to the AfMET region

Regulatory, Pharmacovigilence, logistics and commercial expertise is just a few reasons why NewBridge Pharmaceuticals is your partner-of-choice.

NewBridge team is well-connected to a wide range of partners and key stakeholders in and out of the region, and offers a flexible approach to joint-ventures and partnerships.

Learn what NewBridge partnership can do for you

The AfMET Opportunity

More than 1 billion people reside in the area known as the AfMET region, which encompasses Africa, the Middle East, Turkey, and the Caspian area.

Like most of the Western world, the AfMET region is experiencing sharply rising regional incidence and prevalence of diabetes, obesity, cardiovascular, and oncologic disease. NewBridge has created a regional platform to facilitate the access of our partners' innovative products to the AfMET Region.

Learn more about our territories »

Our Featured Partners

Learn more about our products »

Company News and Press

NEWBRIDGE ANNOUNCES PARTNERSHIP WITH EISAI TO MARKET BREAST CANCER TREATMENT HALAVEN® (ERIBULIN) ACROSS THE MIDDLE EAST

NEWBRIDGE ANNOUNCES PARTNERSHIP WITH EISAI TO MARKET BREAST CANCER TREATMENT HALAVEN® (ERIBULIN) ACROSS THE MIDDLE EAST

 

Read more NewBridge news »